Cargando…

Circulated TGF-β1 and VEGF-A as Biomarkers for Fabry Disease-Associated Cardiomyopathy

Fabry disease (FD) is a lysosomal disorder caused by α-galactosidase A deficiency, resulting in the accumulation of globotriaosylceramide (Gb-3) and its metabolite globotriaosylsphingosine (Lyso-Gb-3). Cardiovascular complications and hypertrophic cardiomyopathy (HCM) are the most frequent manifesta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ivanova, Margarita M., Dao, Julia, Slayeh, Omar Abu, Friedman, Andrew, Goker-Alpan, Ozlem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453505/ https://www.ncbi.nlm.nih.gov/pubmed/37626912 http://dx.doi.org/10.3390/cells12162102

Ejemplares similares

Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases
por: Ivanova, Margarita M., et al.
Publicado: (2019)

Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease
por: Ivanova, Margarita M., et al.
Publicado: (2022)

TRAP5b and RANKL/OPG Predict Bone Pathology in Patients with Gaucher Disease
por: Ivanova, Margarita, et al.
Publicado: (2021)

Rapid Clathrin-Mediated Uptake of Recombinant α-Gal-A to Lysosome Activates Autophagy
por: Ivanova, Margarita M., et al.
Publicado: (2020)

The Interaction of Innate and Adaptive Immunity and Stabilization of Mast Cell Activation in Management of Infusion Related Reactions in Patients with Fabry Disease
por: Limgala, Renuka P., et al.
Publicado: (2020)

Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease
por: Ivanova, Margarita M., et al.
Publicado: (2021)

Fabry Cardiomyopathy
por: Yoon, Jae Yong, et al.
Publicado: (2013)

Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy
por: Loso, Jefferson, et al.
Publicado: (2018)

Optimal therapy in Gaucher disease
por: Goker-Alpan, Ozlem
Publicado: (2010)

Circulating Anti-GB3 Antibody as a Biomarker of Myocardial Inflammation in Patients with Fabry Disease Cardiomyopathy
por: Frustaci, Andrea, et al.
Publicado: (2023)

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
por: Goker-Alpan, Ozlem, et al.
Publicado: (2016)

Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
por: Morrissey, Ryan P, et al.
Publicado: (2011)

Circulating TGF-β1 and VEGF and risk of cancer among liver transplant recipients
por: Engels, Eric A, et al.
Publicado: (2015)

A Case of Fabry Cardiomyopathy
por: Nah, Jong Chun, et al.
Publicado: (2009)

Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease
por: Limgala, Renuka P., et al.
Publicado: (2020)

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
por: Goláň, Lubor, et al.
Publicado: (2015)

Biomarkers of Myocardial Fibrosis: Revealing the Natural History of Fibrogenesis in Fabry Disease Cardiomyopathy
por: Aguiar, Patrício, et al.
Publicado: (2018)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

Biofabrication of an in-vitro bone model for Gaucher disease
por: Banerjee, Dishary, et al.
Publicado: (2023)

Altered Sphingolipids Metabolism Damaged Mitochondrial Functions: Lessons Learned From Gaucher and Fabry Diseases
por: Ivanova, Margarita
Publicado: (2020)

High‐Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease
por: Seydelmann, Nora, et al.
Publicado: (2016)

High‐Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease
Publicado: (2016)

Immune‐Mediated Myocarditis in Fabry Disease Cardiomyopathy
por: Frustaci, Andrea, et al.
Publicado: (2018)

Role of cardiac imaging in Anderson-Fabry cardiomyopathy
por: Serra, Walter, et al.
Publicado: (2019)

Fabry Cardiomyopathy: Current Practice and Future Directions
por: Yim, Jeffrey, et al.
Publicado: (2021)

Fabry Cardiomyopathy: Current Treatment and Future Options
por: Vardarli, Irfan, et al.
Publicado: (2021)

Circulating Biomarkers in Hypertrophic Cardiomyopathy
por: Matthia, Eldon L., et al.
Publicado: (2022)

VEGF and TGF-β are required for the maintenance of the choroid plexus and ependyma
por: Maharaj, Arindel S.R., et al.
Publicado: (2008)

A pilot study of circulating microRNAs as potential biomarkers of Fabry disease
por: Cammarata, Giuseppe, et al.
Publicado: (2018)

Selective screening for lysosomal storage disorders in a large cohort of minorities of African descent shows high prevalence rates and novel variants
por: Limgala, Renuka Pudi, et al.
Publicado: (2021)

Circulating microRNAs in Fabry Disease
por: Xiao, Ke, et al.
Publicado: (2019)

Comparative analysis of right ventricular strain in Fabry cardiomyopathy and sarcomeric hypertrophic cardiomyopathy
por: Meucci, Maria Chiara, et al.
Publicado: (2022)

Potential role of vitamin D deficiency on Fabry cardiomyopathy
por: Drechsler, Christiane, et al.
Publicado: (2013)

Fabry Disease Presenting with Hypertrophic Cardiomyopathy and Tricuspid Regurgitation
por: Cho, Sang-Cheol, et al.
Publicado: (2016)

Roles of the TGF-β–VEGF-C Pathway in Fibrosis-Related Lymphangiogenesis
por: Kinashi, Hiroshi, et al.
Publicado: (2018)

Follistatin Attenuates Myocardial Fibrosis in Diabetic Cardiomyopathy via the TGF-β–Smad3 Pathway
por: Wang, Yinhui, et al.
Publicado: (2021)

Biomarkers in Anderson–Fabry Disease
por: Simonetta, Irene, et al.
Publicado: (2020)

TGFβ1 Induces Senescence and Attenuated VEGF Production in Retinal Pericytes
por: Avramovic, Dragana, et al.
Publicado: (2022)

Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy
por: Vijapurapu, Ravi, et al.
Publicado: (2019)

Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathy
por: Vijapurapu, Ravi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lkt2o9fpbll4d7lhptlls16psr